196 related articles for article (PubMed ID: 22245520)
1. Adjuvant interferon therapy for patients at high risk for recurrent melanoma: an updated systematic review and practice guideline.
Petrella T; Verma S; Spithoff K; Quirt I; McCready D;
Clin Oncol (R Coll Radiol); 2012 Aug; 24(6):413-23. PubMed ID: 22245520
[TBL] [Abstract][Full Text] [Related]
2. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma.
Verma S; Quirt I; McCready D; Bak K; Charette M; Iscoe N
Cancer; 2006 Apr; 106(7):1431-42. PubMed ID: 16511841
[TBL] [Abstract][Full Text] [Related]
3. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.
Mocellin S; Pasquali S; Rossi CR; Nitti D
J Natl Cancer Inst; 2010 Apr; 102(7):493-501. PubMed ID: 20179267
[TBL] [Abstract][Full Text] [Related]
4. Interferon alpha for the adjuvant treatment of cutaneous melanoma.
Mocellin S; Lens MB; Pasquali S; Pilati P; Chiarion Sileni V
Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008955. PubMed ID: 23775773
[TBL] [Abstract][Full Text] [Related]
5. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials.
Wheatley K; Ives N; Hancock B; Gore M; Eggermont A; Suciu S
Cancer Treat Rev; 2003 Aug; 29(4):241-52. PubMed ID: 12927565
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant therapy in melanoma.
Mohr P; Weichenthal M; Hauschild A
Onkologie; 2003 Jun; 26(3):227-33. PubMed ID: 12845206
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous melanoma: interferon alpha adjuvant therapy for patients at high risk for recurrent disease.
Lens M
Dermatol Ther; 2006; 19(1):9-18. PubMed ID: 16405565
[TBL] [Abstract][Full Text] [Related]
8. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials.
Lens MB; Dawes M
J Clin Oncol; 2002 Apr; 20(7):1818-25. PubMed ID: 11919239
[TBL] [Abstract][Full Text] [Related]
9. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma.
McMasters KM; Edwards MJ; Ross MI; Reintgen DS; Martin RC; Urist MM; Noyes RD; Sussman JJ; Stromberg AJ; Scoggins CR
Ann Surg; 2010 Sep; 252(3):460-5; discussion 465-6. PubMed ID: 20739846
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H
Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant treatment of anogenital warts with systemic interferon: a systematic review and meta-analysis.
Westfechtel L; Werner RN; Dressler C; Gaskins M; Nast A
Sex Transm Infect; 2018 Feb; 94(1):21-29. PubMed ID: 28819018
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis.
Ives NJ; Suciu S; Eggermont AMM; Kirkwood J; Lorigan P; Markovic SN; Garbe C; Wheatley K;
Eur J Cancer; 2017 Sep; 82():171-183. PubMed ID: 28692949
[TBL] [Abstract][Full Text] [Related]
13. Systemic adjuvant therapy for adult patients at high risk for recurrent melanoma: A systematic review.
Baetz TD; Fletcher GG; Knight G; McWhirter E; Rajagopal S; Song X; Petrella TM
Cancer Treat Rev; 2020 Jul; 87():102032. PubMed ID: 32473511
[TBL] [Abstract][Full Text] [Related]
14. Determination of potential adjuvant systemic therapy benefits for patients with resected cutaneous melanomas.
Thomé SD; Loprinzi CL; Heldebrant MP
Mayo Clin Proc; 2002 Sep; 77(9):913-7. PubMed ID: 12233924
[TBL] [Abstract][Full Text] [Related]
15. Systemic adjuvant therapy for adult patients at high risk for recurrent cutaneous or mucosal melanoma: an Ontario Health (Cancer Care Ontario) clinical practice guideline.
Petrella TM; Fletcher GG; Knight G; McWhirter E; Rajagopal S; Song X; Baetz TD
Curr Oncol; 2020 Feb; 27(1):e43-e52. PubMed ID: 32218667
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?
Schuchter LM
J Clin Oncol; 2004 Jan; 22(1):7-10. PubMed ID: 14665612
[No Abstract] [Full Text] [Related]
17. The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients.
Eggermont AMM; Dummer R
Eur J Cancer; 2017 Nov; 86():101-105. PubMed ID: 28968566
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.
Eggermont AM; Suciu S; Testori A; Santinami M; Kruit WH; Marsden J; Punt CJ; Salès F; Dummer R; Robert C; Schadendorf D; Patel PM; de Schaetzen G; Spatz A; Keilholz U
J Clin Oncol; 2012 Nov; 30(31):3810-8. PubMed ID: 23008300
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
[TBL] [Abstract][Full Text] [Related]
20. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
Eggermont AM; Suciu S; MacKie R; Ruka W; Testori A; Kruit W; Punt CJ; Delauney M; Sales F; Groenewegen G; Ruiter DJ; Jagiello I; Stoitchkov K; Keilholz U; Lienard D;
Lancet; 2005 Oct; 366(9492):1189-96. PubMed ID: 16198768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
